Clinical trial
Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)
NCT00878761 is registered in ClinicalTrials.gov with Stromedix, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)
- Lead sponsor
- Stromedix, Inc.
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- September 30, 2010
- Completion date
- December 31, 2011
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic allograft dysfunction